Fig. 5.
In vivo targeting to MMM results in functional antitumor CTL responses. Mice were i.v. immunized either with 5 μg αSiglec-1-OVA, 5 μg αDEC205-OVA (both together with 25 μg αCD40), or 5 × 107 pfu AdOVA. After 7 days, mice were injected with B16 melanoma cells expressing OVA and luciferase in the portal vein. Tumor growth was measured on day 5 after tumor implantation by in vivo imaging (IVIS200; Xenogen). Error bars indicate SEM, n = 3–4 mice per group. ***P < 0.01 versus control. P values were calculated by one-way ANOVA with Bonferroni correction (GraphPad Prism 4 software).